Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer causes more aggressive progression of disease and poorer outcomes for patients. HER2-targeted medicines used as neoadjuvant systemic therapy could improve clinical outcomes in early-stage or locally advanced breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunasekara, Agampodi Danushi M., Anothaisintawee, Thunyarat, Youngkong, Sitaporn, Ha, Nguyen T., McKay, Gareth J., Attia, John, Thakkinstian, Ammarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833584/
https://www.ncbi.nlm.nih.gov/pubmed/35158791
http://dx.doi.org/10.3390/cancers14030523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833584/
https://www.ncbi.nlm.nih.gov/pubmed/35158791
http://dx.doi.org/10.3390/cancers14030523

Ejemplares similares